Last Updated

18 Jan 2019

The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy

Objectives

The investigators aim to determine optimal timing of primaquine administration in addition to ACT by comparing administration on day 0 with administration on day 2.

Principal Institution(s)

Principal Investigator
Funding Information
GBP 80,435
Rationale and Abstract

The investigators' Hypothesis is that "The correct timing of gametocytocidal drug in combination with an effective Artemisinin Combination Therapy can limit the infectiousness of malaria-infected individuals to less than one week after initiation of treatment".

The investigators' primary endpoints are gametocyte prevalence and density by microscopy and Quantitative Nucleic Acid Based Amplification (QT-NASBA) on day 14, which will be compared between the two primaquine treatment arms.

ClinicalTrials.gov Identifier: NCT01906788

Study Design
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Thematic Categories

Date

2013 May - 2013 Oct

Total Project Funding

$104,080

Funding Details

Project Site